Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Speyeder999on Aug 10, 2021 8:25pm
109 Views
Post# 33682860

RE:RE:RE:How much is needed to start Phase I?

RE:RE:RE:How much is needed to start Phase I?Mole, you bring up an excellent point. What's the point in coming out with a  news release if you don't plan on giving an update at least once every 6-12 months.
Case  in point: the Covid serology  test. Perhaps many here  are comfortable with the absence of news on this matter because it doesn't fall in the company's core field of research, but you'd think that an update by now would be expected, no? If not, why bother to put out some commercialization news report? They had a perfect opportunity to correct this when they updated their " corporate update" but they failed to do so. The company is using funds, resources and time to do research on serology tests but doesn't consider this to fall under a corporate banner because.......? ....it's a joint venture? I find this very unprofessional, but that's just my personal opinion. We still don't know it their test is submitted for review to the FDA or Health Canada for approval as of today and this seems normal?
I'm still hoping that we are left in the dark for a reason and that something positive still comes out of this, as little as it may seem.
<< Previous
Bullboard Posts
Next >>